Anavex Life Sciences Corp (AVXL)

[kevindenver]

Merck Canada is providing the funding for general research with Anavex 2-73 and 3-71 in the mix.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409318/

"ACC is the holder of the Charles E. Frosst/Merck endowed Chair in Pharmacology and a member of the Canadian Consortium on Neurodegeneration in Aging. The authors are grateful for the unrestricted support provided by Merck Canada."

Regarding 3-71:

Given the complexity of AD pathophysiology, drugs that can target multiple receptors or impaired signaling pathways would likely offer a therapeutic advantage over more conventional single-target drug, as illustrated in the previous section. In that regards, the novel compound AF710B (aka ANAVEX 3-71) merits further attention. It is a combined selective allosteric M1 muscarinic and sigma 1 receptor agonist (Fisher et al., 2016). Targeting sigma 1 receptor has been shown to provide neuroprotection and anti-amnestic properties (Marrazzo et al., 2005; Maurice and Su, 2009; Villard et al., 2011). Combined with M1 muscarinic receptor-mediated effects on APP metabolism, it would confer AF710B a pharmacological profile of interest to tackle various pathological aspects of AD.

2-73 is in the references:

Villard V., Espallergues J., Keller E., Vamvakides A., Maurice T. (2011). Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J. Psychopharmacol. 25 1101–1117. 10.1177/0269881110379286 [PubMed] [CrossRef] [Google Scholar]